Search Results

ARMGO Pharma, Inc. (ARMGO), a clinical stage biopharmaceutical company advancing a novel class of small molecule drugs known as Rycals®, announced today the publication of the results from a Phase 1b study of its Rycal ARM210 (also known as S48168), for the treatment of Ryanodine Receptor 1 Related Myopathies (RYR1-RM), an orphan muscle disease.

ARMGO Pharma, Inc. announced the enrollment of the first patient in a Phase 2 proof of concept clinical trial using its Rycal ARM210, for the treatment of Catecholaminergic Polymorphic Ventricular Tachycardia.

One of the lowest paid CEOs in pharma—and one of the only woman leading a top-tier giant—is set to receive up to $27.2 million in 2025.

President Trump also refused to promise pharma execs that he would hamstring the IRA’s drug negotiation program.

As the Q4 2024 pharma earnings period rolls on through the first month of President Donald Trump’s second term, executives find themselves faced with policy questions ranging from the Inflation Reduction Act to RFK Jr.